Elvitegravir
China [CN] Ettelavir belongs to 4-quinolone-3-glyoxyacid antiretroviral drugs. It is an HIV integrase inhibitor that can inhibit the transfer of viral DNA strands by HIV integrase, thereby affecting viral replication. HIV integrase inhibitors are the third type of anti-HIV drugs discovered after nucleoside/non-nucleoside anti-reverse transcriptase inhibitors and protease inhibitors. The first integrase inhibitor was Ritagvir developed by Merck, which was approved by the FDA in 2007 for HIV /AIDS infections. Ettelavir, developed by Gilead Sciences, is the second integrase inhibitor approved by the FDA in 2012 after Retegvir, and it is also the first quinolone integrase inhibitor against HIV. The virological effects of these two drugs are similar, but ettelavir only needs to be taken orally once a day, and its compliance is better than that of ritagvir (twice a day). It can also inhibit viruses that have developed resistance to other anti-AIDS drugs, and has good compliance and tolerance.
Click enlarge Image